EA202090205A1 - Антагонист рецептора ангиотензина ii для предотвращения или лечения системных заболеваний у котов - Google Patents

Антагонист рецептора ангиотензина ii для предотвращения или лечения системных заболеваний у котов

Info

Publication number
EA202090205A1
EA202090205A1 EA202090205A EA202090205A EA202090205A1 EA 202090205 A1 EA202090205 A1 EA 202090205A1 EA 202090205 A EA202090205 A EA 202090205A EA 202090205 A EA202090205 A EA 202090205A EA 202090205 A1 EA202090205 A1 EA 202090205A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
prevention
sartan
receptor antagonist
angiotenzine
Prior art date
Application number
EA202090205A
Other languages
English (en)
Inventor
Балаж Альбрехт
Свен Анке
Саския Кляй
Штефан Йоханнес Ленер
Маркус Штарк
Энн Мишель Трас
Таня Маргрит Циммеринг
Original Assignee
Бёрингер Ингельхайм Ветмедика Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бёрингер Ингельхайм Ветмедика Гмбх filed Critical Бёрингер Ингельхайм Ветмедика Гмбх
Publication of EA202090205A1 publication Critical patent/EA202090205A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61D—VETERINARY INSTRUMENTS, IMPLEMENTS, TOOLS, OR METHODS
    • A61D7/00—Devices or methods for introducing solid, liquid, or gaseous remedies or other materials into or onto the bodies of animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Описан способ для профилактики или лечения гипертонии у кота, нуждающегося в таком лечении. Способ включает введение терапевтически эффективного количества антагониста рецептора ангиотензина II первого типа (AT-1) (сартана) коту, где терапевтически эффективное количество сартана вводят в суточном дозируемом количестве, которое изменяется в течение периода лечения, суточное дозируемое количество сартана для первого периода времени в течение периода лечения составляет от 1,0 до 5,0 мг/кг веса тела и суточное дозируемое количество сартана снижено для второго периода времени после первого периода времени в течение периода лечения.
EA202090205A 2017-07-07 2018-07-05 Антагонист рецептора ангиотензина ii для предотвращения или лечения системных заболеваний у котов EA202090205A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762529587P 2017-07-07 2017-07-07
PCT/EP2018/068189 WO2019008077A1 (en) 2017-07-07 2018-07-05 ANTAGONIST OF THE ANGIOTENSIN II RECEPTOR FOR THE PREVENTION OR TREATMENT OF SYSTEMIC DISEASES IN CATS

Publications (1)

Publication Number Publication Date
EA202090205A1 true EA202090205A1 (ru) 2020-06-02

Family

ID=62904440

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202090205A EA202090205A1 (ru) 2017-07-07 2018-07-05 Антагонист рецептора ангиотензина ii для предотвращения или лечения системных заболеваний у котов

Country Status (22)

Country Link
US (2) US10905676B2 (ru)
EP (2) EP3648761B1 (ru)
JP (2) JP7050893B2 (ru)
KR (2) KR20200026975A (ru)
CN (1) CN110785168A (ru)
AR (1) AR112265A1 (ru)
AU (1) AU2018295387B2 (ru)
BR (1) BR112020000194A2 (ru)
CA (1) CA3067918A1 (ru)
DK (1) DK3648761T3 (ru)
EA (1) EA202090205A1 (ru)
ES (1) ES2979279T3 (ru)
FI (1) FI3648761T3 (ru)
HR (1) HRP20240703T1 (ru)
LT (1) LT3648761T (ru)
NZ (1) NZ759782A (ru)
PL (1) PL3648761T3 (ru)
PT (1) PT3648761T (ru)
RS (1) RS65570B1 (ru)
SI (1) SI3648761T1 (ru)
TW (1) TW201919703A (ru)
WO (1) WO2019008077A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022540077A (ja) 2019-07-09 2022-09-14 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー イヌの高血圧の治療のためのテルミサルタン
MX2022000429A (es) 2019-07-09 2022-04-25 Boehringer Ingelheim Vetmedica Gmbh Telmisartan para el tratamiento de la enfermedad renal cronica en perros.

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5671074A (en) 1979-11-12 1981-06-13 Takeda Chem Ind Ltd 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
CA1334092C (en) 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
US5015651A (en) 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists
CA1338238C (en) 1988-01-07 1996-04-09 David John Carini Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
US4880804A (en) 1988-01-07 1989-11-14 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking benzimidazoles
IE70593B1 (en) 1989-09-29 1996-12-11 Eisai Co Ltd Biphenylmethane derivative the use of it and pharmacological compositions containing same
ATE134624T1 (de) 1990-02-19 1996-03-15 Ciba Geigy Ag Acylverbindungen
IE910913A1 (en) 1990-03-20 1991-09-25 Sanofi Sa N-substituted heterocyclic derivates, their preparation¹and pharmaceutical compositions containing them
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
IL99246A0 (en) 1990-09-10 1992-07-15 Abbott Lab Angiotensin ii receptor antagonists and pharmaceutical compositions containing them
GB9027210D0 (en) 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
US6028091A (en) 1990-12-14 2000-02-22 Smithkline Beecham Plc Medicament
SI9210098B (sl) 1991-02-06 2000-06-30 Dr. Karl Thomae Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo
US5196537A (en) 1991-03-21 1993-03-23 G. D. Searle & Co. 5-apylheteroarylalkyl-1,3,5-trisubstituted-1,2,4-triazole compounds for treatment of circulatory disorders
GB9110636D0 (en) 1991-05-16 1991-07-03 Glaxo Group Ltd Chemical compounds
NZ251741A (en) 1992-04-13 1997-06-24 Zeneca Ltd Use of angiotensin ii antagonists for treating disease conditions associated with impaired neuronal conduction velocity
AU696868B2 (en) 1994-03-29 1998-09-17 Merck & Co., Inc. Treatment of atherosclerosis with angiotensin II receptor blocking imidazoles
US6358986B1 (en) 1999-01-19 2002-03-19 Boehringer Ingelheim Pharma Kg Polymorphs of telmisartan
DE19901921C2 (de) 1999-01-19 2001-01-04 Boehringer Ingelheim Pharma Polymorphe von Telmisartan, Verfahren zu deren Herstellung und deren Verwendung zur Herstellung eines Arzneimittels
DE10018401A1 (de) 2000-04-13 2001-10-25 Boehringer Ingelheim Pharma Verwendung von Bradycardica bei der Behandlung von mit Hypertrophie einhergehenden Myocarderkrankungen und neue Arzneimittelkombinationen
WO2002092081A1 (en) 2001-05-14 2002-11-21 Merck & Co., Inc. Method of treatment
DE10153737A1 (de) 2001-10-31 2003-05-28 Boehringer Ingelheim Pharma Kristallines Natriumsalz des Telmisartans, Verfahren zu dessen Herstellung und dessen Verwendung zur Herstellung eines Arzneimittels
US8980870B2 (en) 2002-09-24 2015-03-17 Boehringer Ingelheim International Gmbh Solid telmisartan pharmaceutical formulations
EP1579862A1 (en) 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
US20070026026A1 (en) 2005-08-01 2007-02-01 David Delmarre Oral liquid losartan compositions
EP1908469A1 (en) * 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
CA2653011A1 (en) * 2008-12-03 2010-06-03 Apotex Technologies Inc Method and apparatus for packaging and dispensing pharmaceuticals
MX346039B (es) * 2009-05-20 2017-03-03 Boehringer Ingelheim Vetmedica Gmbh Solucion farmaceutica bebible de telmisartan.
EP3307069B1 (en) * 2015-06-10 2021-08-04 Hackensack University Medical Center Use of telmisartan to prevent and treat graft versus host disease and other alloimmune and autoimmune diseases
BR112019004033A2 (pt) 2016-09-07 2019-05-28 Saniona As composição farmacêutica oral estável, processo para preparar a composição, método, e, uso da composição farmacêutica

Also Published As

Publication number Publication date
FI3648761T3 (fi) 2024-05-21
JP7402907B2 (ja) 2023-12-21
AU2018295387B2 (en) 2024-02-15
AU2018295387A1 (en) 2020-01-02
US10905676B2 (en) 2021-02-02
EP3648761B1 (en) 2024-03-13
LT3648761T (lt) 2024-06-10
AR112265A1 (es) 2019-10-09
EP4299120A3 (en) 2024-03-06
ES2979279T3 (es) 2024-09-25
RS65570B1 (sr) 2024-06-28
EP3648761A1 (en) 2020-05-13
WO2019008077A1 (en) 2019-01-10
US20210106564A1 (en) 2021-04-15
DK3648761T3 (da) 2024-06-24
JP7050893B2 (ja) 2022-04-08
JP2022075670A (ja) 2022-05-18
BR112020000194A2 (pt) 2020-07-07
PL3648761T3 (pl) 2024-07-22
KR20200026975A (ko) 2020-03-11
SI3648761T1 (sl) 2024-07-31
US20190008831A1 (en) 2019-01-10
CN110785168A (zh) 2020-02-11
TW201919703A (zh) 2019-06-01
PT3648761T (pt) 2024-06-05
KR20230161541A (ko) 2023-11-27
JP2020526516A (ja) 2020-08-31
CA3067918A1 (en) 2019-01-10
EP4299120A2 (en) 2024-01-03
NZ759782A (en) 2023-06-30
HRP20240703T1 (hr) 2024-08-16

Similar Documents

Publication Publication Date Title
MA39070A1 (fr) Anticorps anti-cd38 spécifiques pour le traitement de cancers humains
EA201100814A1 (ru) Фармацевтические формы применения, содержащие нифедипин или низолдипин и антагонист ангиотензина-ii и/или диуретик
MA31396B1 (fr) Therapie de combinaison avec un compose agissant comme inhibiteur de recepteur a l'adp de plaquettes
MX2023001468A (es) Tratamiento de cancer de prostata.
MX2018005715A (es) Uso de antagonistas del receptor ep4 para el tratamiento de cancer de higado asociado con nash.
EA201490163A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
EA201990249A1 (ru) Применение и режим дозирования терапевтических агентов при эндометриозе
CA2939464A1 (en) Use of anti-ccr5 antibodies in graft versus host disease
JP2015531373A5 (ru)
MX2023004366A (es) Composiciones para el tratamiento de la hipertension.
CY1114266T1 (el) Ανταγωνιστης υποδοχεα της αγγειοτενσινης ιι για τη θεραπευτικη αγωγη συστημικων νοσων σε γατες
EA202090205A1 (ru) Антагонист рецептора ангиотензина ii для предотвращения или лечения системных заболеваний у котов
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
MX2023000187A (es) Dosificacion de vibegron para el tratamiento de vejiga sobreactiva.
MX2021003681A (es) Composiciones y metodos para el tratamiento de desordenes inflamatorios.
WO2018027084A3 (en) Combination of glucagon receptor antagonists and pi3k pathway inhibitors for the treatment of cancer
MX2019006773A (es) Dexmedetomidina o medetomidina para uso en el tratamiento de la ansiedad por separacion en perros.
MA29722B1 (fr) Schema posologique pour le prasugrel
RU2016124538A (ru) Антагонисты гастрина для лечения и профилактики остеопороза
BR112022007348A2 (pt) Métodos para tratar condições relacionadas ao receptor s1p1
MX2021004603A (es) Dosificacion.
MX2023012030A (es) Combinacion que comprende un inhibidor especifico de histona desacetilasa 6 (hdac6) y al menos un inhibidor del punto de control del antigeno 4 del linfocito t citotoxico (ctla4).
MX2022000426A (es) Telmisartan para el tratamiento de la hipertension en perros.
EA202090416A1 (ru) Способы лечения симптомов гастропареза с использованием велусетрага
MX2022000429A (es) Telmisartan para el tratamiento de la enfermedad renal cronica en perros.